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FIGURE 2 18F-Flouride Uptake for a Given CT Calcium Score
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Patients with higher than expected 18F-ﬂuoride uptake for a given CT calcium score (dots in
red above regression line) demonstrated disease progression rates 3-fold greater than those
with lower than expected uptake (dots in blue below regression line). The samewas not true
for 18F-ﬂuorodeoxyglucose. AS ¼ aortic stenosis; TBRMDS ¼most diseased segment tissue:
background ratio; 18F-NaF ¼ 18F-ﬂuoride.
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1201signiﬁcant difference was observed (median change in
calcium score: 231 [IQR: 79 to 446] AU/year vs. 124
[IQR: 61 to 321] AU/year; p ¼ 0.14). Neither tracer
offered independent prediction of clinical outcomes
after correction for CT calcium scoring, perhaps
reﬂecting the small number of events and again the
collinearity between imaging parameters.
In conclusion we demonstrated that both 18F-ﬂuo-
ride and 18F-FDG predicted disease progression and
adverse clinical outcomes in aortic stenosis. In partic-
ular, 18F-ﬂuoride provided excellent prediction of the
change in CT calcium score, appearing to be of incre-
mental value to baseline CT imaging. Larger studies are
required to conﬁrm the incremental predictive value
of PET compared with CT. However, our data would
support PET/CT as a novel method for measuring dis-
ease activity in aortic stenosis, with the ability to
predict its natural history. This may be of particular
value in studies investigating novel therapies, in
which beneﬁcial treatment effects are likely to be
detected rapidly without the need for protracted
follow-up. (Role of Active Valvular Calciﬁcation
and Inﬂammation in Patients With Aortic Stenosis;
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The Devil Is in the DetailsWe read with great interest the paper by Pant et al. (1)
regarding trends in infective endocarditis (IE) inci-
dence using the Nationwide Inpatient Sample (NIS)
database to address a nagging question that has right-
fully garnered much attention and gravity: have recent
changes in IE prophylaxis guidelines for dental pro-
cedures in this country and abroad resulted in an
increase in IE incidence caused by viridans group
streptococci (VGS)? As investigators who have previ-
ously used the NIS database (2,3), we pose 2 concerns
to Pant et al. First, they unfortunately used ICD-9-CM
codes that included enterococcal (04104) and non-
VGS (038.2 Streptococcus pneumoniae septicemia, and
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1202beta-hemolytic streptococci: 04100 Group A strepto-
cocci, 04102 Group B, 04103 Group C, 04105 Group G)
IE cases under the category of “streptococcal.” This
has major implications as we evaluate the risk, if any,
of dental procedures and the subsequent development
of IE caused by VGS. In this regard, our ﬁndings (2,3)
and those of Bor et al. (4), which were both derived
from the same database (NIS), did not demonstrate an
increase in IE incidence caused by VGS.
Second, the work by Pant et al. was presented at the
American College of Cardiology 2014 meeting in a pre-
liminary format (5) and they identiﬁed an increase in IE
incidence from2000 to 2011 causedby staphylococci, but
reported that there was no increase in IE caused by
“VGE” (which we assume was in reference to VGS).
Interestingly, therewasnodesignation for “enterococci”
in that abstract for the 2014 meeting, or in the current
publication (1).
The enterococcal designation is an important one
because these organisms are a predominant cause of
IE and its prevalence seems to be increasing. For
example, an extensive systematic review by Slipczuk
et al. (5) of IE over the past 5 decades (up through
2011) demonstrated the prevalence of staphylococcal
and enterococcal IE had both increased; in contrast,
VGS IE had declined.
The only conclusions that we can derive from the
current publication (1) is that there was a key error in
the selection of ICD-9-CM codes to deﬁne the micro-
biology of IE and that has likely resulted in a ﬂawed
conclusion that “there has been a signiﬁcant rise in
the incidence of streptococcus IE following the 2007
guideline revision.” Therefore, we request that Pant
et al. perform a focused analysis of IE caused by VGS
to clarify the issue.
These database reviews are critical as guidelines
committees struggle to answer one of the most
important questions in IE prevention: is antibiotic
prophylaxis for certain dental procedures efﬁcacious?
This struggle, in large part, is caused by the lack of
a randomized controlled clinical trial, as highlighted
in an accompanying editorial and has been a plea
echoed for decades.
Going forward and until clinical trial data are
available, a second plea seems in order. In studies
of cardiovascular infections, a cadre of experts
from different ﬁelds should be included, as done in
individual patient management of IE.*Daniel C. DeSimone, MD
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The Devil Is in the DetailsWe thank Dr. DeSimone and colleagues for their in-
terest in our paper. In our study, we focused on
infective endocarditis (IE) microbiology to Staphy-
lococcus, Streptococcus, gram-negative, and fungal
organisms. Our study differs from previous papers
from the Nationwide Inpatient Sample database (1,2)
in 2 aspects. First, we did include infections from all
streptococcal groups (A, B, C, D [enterococcus], G,
and unspeciﬁed) and did not report viridans group
Streptococcus (VGS) separately. Second, previous
studies on IE trends in the United States had a very
limited follow-up of only 2 years after the guideline
publication. Longer follow-up studies are necessary
to assess the impact of any “practice changing”
guideline because it takes years to note the impact
of such change. Similar observations were made in
the United Kingdom where a steady incidence of IE
was noted for the ﬁrst 2 years after publication of
new guidelines, whereas a 5-year follow-up detected
a signiﬁcant rise (3,4). Our study emphasizes the
